IL276211B2 - HU14.18K322A monoclonal antibody production process - Google Patents

HU14.18K322A monoclonal antibody production process

Info

Publication number
IL276211B2
IL276211B2 IL276211A IL27621120A IL276211B2 IL 276211 B2 IL276211 B2 IL 276211B2 IL 276211 A IL276211 A IL 276211A IL 27621120 A IL27621120 A IL 27621120A IL 276211 B2 IL276211 B2 IL 276211B2
Authority
IL
Israel
Prior art keywords
population
afucosylated
antibodies
monoclonal antibodies
monoclonal
Prior art date
Application number
IL276211A
Other languages
English (en)
Hebrew (he)
Other versions
IL276211A (en
IL276211B1 (en
Original Assignee
St Jude Childrens Res Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Res Hospital Inc filed Critical St Jude Childrens Res Hospital Inc
Publication of IL276211A publication Critical patent/IL276211A/en
Publication of IL276211B1 publication Critical patent/IL276211B1/en
Publication of IL276211B2 publication Critical patent/IL276211B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL276211A 2018-02-15 2019-02-15 HU14.18K322A monoclonal antibody production process IL276211B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862630971P 2018-02-15 2018-02-15
PCT/US2019/018169 WO2019161167A1 (en) 2018-02-15 2019-02-15 Process for producing hu14.18k322a monoclonal antibody

Publications (3)

Publication Number Publication Date
IL276211A IL276211A (en) 2020-09-30
IL276211B1 IL276211B1 (en) 2024-10-01
IL276211B2 true IL276211B2 (en) 2025-02-01

Family

ID=67620073

Family Applications (2)

Application Number Title Priority Date Filing Date
IL276211A IL276211B2 (en) 2018-02-15 2019-02-15 HU14.18K322A monoclonal antibody production process
IL315353A IL315353A (en) 2018-02-15 2019-02-15 HU14.18K322A monoclonal antibody production process

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL315353A IL315353A (en) 2018-02-15 2019-02-15 HU14.18K322A monoclonal antibody production process

Country Status (9)

Country Link
US (1) US20210002384A1 (https=)
EP (1) EP3752535A4 (https=)
JP (1) JP2021517805A (https=)
KR (1) KR20200123156A (https=)
CN (1) CN112105647A (https=)
AU (1) AU2019220667A1 (https=)
CA (1) CA3091344A1 (https=)
IL (2) IL276211B2 (https=)
WO (1) WO2019161167A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7494722B2 (ja) * 2020-12-16 2024-06-04 株式会社島津製作所 糖鎖質量分析データ解析装置、及び糖鎖質量分析データ解析用プログラム
EP4531918A2 (en) * 2022-06-01 2025-04-09 TG Therapeutics Inc. Commercial-scale recombinant protein production in rat hybridoma cells
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN115894604B (zh) * 2022-12-16 2024-01-23 康日百奥生物科技(苏州)有限公司 重组蛋白澄清纯化方法
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KORY L. ALDERSON ET AL,, CLINICAL CANCER THERAPY BY NK CELLS VIA ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY, 1 January 2011 (2011-01-01) *
R.K. YANG ET AL,, ANTI-GD2 STRATEGY IN THE TREATMENT OF NEUROBLASTOMA, 1 October 2010 (2010-10-01) *
ROSENBERG E ET AL,, ULTRAFILTRATION CONCENTRATION OF MONOCLONAL ANTIBODY SOLUTIONS: DEVELOPMENT OF AN OPTIMIZED METHOD MINIMIZING AGGREGATION, 21 June 2009 (2009-06-21) *
SARA M. FEDERICO ET AL,, A PILOT TRIAL OF HUMANIZED ANTI-GD2 MONOCLONAL ANTIBODY (HU14.18K322A) WITH CHEMOTHERAPY AND NATURAL KILLER CELLS IN CHILDREN WITH RECURRENT/REFRACTORY NEUROBLASTOMA, 1 November 2017 (2017-11-01) *
SORKIN L S ET AL,, ANTI-GD" 2 WITH AN FC POINT MUTATION REDUCES COMPLEMENT FIXATION AND DECREASES ANTIBODY-INDUCED ALLODYNIA, 1 April 2010 (2010-04-01) *
YOSHINOBU KONNO ET AL,, FUCOSE CONTENT OF MONOCLONAL ANTIBODIES CAN BE CONTROLLED BY CULTURE MEDIUM OSMOLALITY FOR HIGH ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY, 1 May 2012 (2012-05-01) *

Also Published As

Publication number Publication date
IL276211A (en) 2020-09-30
JP2021517805A (ja) 2021-07-29
EP3752535A1 (en) 2020-12-23
CN112105647A (zh) 2020-12-18
CA3091344A1 (en) 2019-08-22
IL315353A (en) 2024-11-01
KR20200123156A (ko) 2020-10-28
AU2019220667A1 (en) 2020-09-17
EP3752535A4 (en) 2021-12-01
US20210002384A1 (en) 2021-01-07
WO2019161167A1 (en) 2019-08-22
IL276211B1 (en) 2024-10-01

Similar Documents

Publication Publication Date Title
IL276211B2 (en) HU14.18K322A monoclonal antibody production process
RU2008113220A (ru) Способ получения белков с использованием соединений, препятствующих старению
Matanguihan et al. Upstream continuous processing: recent advances in production of biopharmaceuticals and challenges in manufacturing
JP2021517805A5 (https=)
WO2002101019A3 (en) Methods of culturing animal cells and polypeptide production in animal cells
CA2693101A1 (en) Culture medium for haemophilus influenzae type b
TW201514305A (zh) 製造單株抗體之改良方法
WO2020135747A1 (zh) 一种优化的体外无细胞蛋白合成体系及其应用
CN105255810A (zh) 一种适合昆虫细胞Sf-9的无血清无动物源培养基
WO2021030617A3 (en) Improved oligosaccharide production in yeast
JP2020505915A (ja) Ｌ−アラニル−ｌ−グルタミン生合成酵素をコードする遺伝子およびその用途
Mosser et al. Fractionation of yeast extract by nanofiltration process to assess key compounds involved in CHO cell culture improvement
Zhang et al. Synthetic sRNA‐based engineering of Escherichia coli for enhanced production of full‐length immunoglobulin G
WO2022243314A3 (en) Methods of producing hmo blend profiles with lnfp-i and 2'-fl as the predominant compounds
CN104302759A (zh) 用于真核细胞的培养基
JP5951953B2 (ja) 新規ジペプチド合成酵素およびそれを用いたジペプチドの製造法
CN103122322A (zh) 一种用于生产谷胱甘肽的毕赤酵母工程菌
CN104561076A (zh) 一种高产l-丝氨酸重组谷氨酸棒杆菌的构建及其发酵方法
KR20180054344A (ko) 와이셀라 시바리아 균주의 대량 생산 방법 및 상기 균주의 배양용 배지 조성물
CN110951766B (zh) 利用重组谷氨酸棒杆菌代谢甘露醇合成l-鸟氨酸的方法
CN108715827B (zh) 酪氨酸酚裂解酶的胞外表达及其应用
JP2013081404A (ja) 新規ジペプチド合成酵素およびそれを用いたジペプチドの製造法
US11098379B2 (en) Composition for detecting potato virus Y including M13KO7 bacteriophage and kit including the same
CN110862940B (zh) 一种谷氨酸棒杆菌工程菌及其在制备l-色氨酸中的应用
US20130210075A1 (en) Enhanced protein expression